2 Recent Biotech IPOs That Could Be Worth A Speculative Buy

A company using artificial intelligence in the drug discovery and validation process and a company developing long-lasting “irreversible” drugs for the treatment of certain cancers are a pair of recent biotech IPOs that “have unique value for investors that could make them worth a (speculative) buy,” advises the author of today’s article. For more on these two hot biotech IPOs, CLICK HERE.